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Abstract
Background: Myostatin is a key negative regulator of muscle growth and development, whose activity has important
implications for the treatment of muscle wastage disorders. Piedmontese cattle display a double-muscled phenotype
associated with the expression of C313Y mutant myostatin. In vivo, C313Y myostatin is proteolytically processed,
exported and circulated extracellularly but fails to correctly regulate muscle growth. The C313Y mutation removes the
C313-containing disulphide bond, an integral part of the characteristic TGF-b cystine-knot structural motif.
Results: Here we present in vitro analysis of the structure and stability of the C313Y myostatin protein that reveals
significantly decreased covalent dimerisation for C313Y myostatin accompanied by a loss of structural stability compared
to wild type. The C313Y myostatin growth factor, processed from full length precursor protein, fails to inhibit C2C12
myoblast proliferation in contrast to wild type myostatin. Although structural modeling shows the substitution of tyrosine
causes structural perturbation, biochemical analysis of additional disulphide mutants, C313A and C374A, indicates that an
intact cystine-knot motif is a major determinant in myostatin growth factor stability and covalent dimerisation.
Conclusions: This research shows that the cystine-knot structure is important for myostatin dimerisation and
stability, and that disruption of this structural motif perturbs myostatin signaling.
Background
Myostatin is a member of the transforming growth factor-
b (TGF-b) superfamily of growth and differentiation fac-
tors, acting as a primary negative regulator of muscle
development and growth [1,2]. Myostatin over expression
in animal models induces profound muscle and fat loss
analogous to that seen in human cachexia syndromes
[3,4]. Myostatin signaling can have negative consequences
in a diseased background such as the muscular dystrophies
[5] and may contribute to cachexia associated with many
chronic disease states [3] including HIV [6] and cancer
[7]. Hence myostatin has been suggested to hold exciting
potential for inhibitory targeting in a wide range of muscle
wastage diseases [8,9].
Similar to other TGF-b family members myostatin is
translated as a precursor protein (MstnPP) consisting of
an N-terminal signal sequence, a propeptide domain
(residues 21-266) and a growth factor domain (MstnGF,
residues 267-374) that contains the characteristic cystine-
knot motif [10,11] and dimerises at the C-terminus via an
intermolecular disulfide bond [12-14]. The propeptide
region plays a chaperone role assisting folding of the
growth factor region [15,16] before furin proteolysis at a
conserved RSRR sequence [1,14]. The propeptide
remains non-covalently associated with the mature dimer
regulating its activity and targeting in the latent complex
[14,17]. Myostatin remains latent until a second activat-
ing cleavage event in the propeptide region that disrupts
the association [18,19].
A number of myostatin null mutations that result in a
double-muscled phenotype have been documented. In one
human case a child has increased muscle mass, is unusually
strong and does not show any negative effects from the
mutation [20]. Myostatin null mutations have also been
identified in Texel sheep [1] and racing whippets [21].
Double-muscled cattle breeds such as the Belgian Blue
have been recognized for almost 200 years [1]. The major-
ity of myostatin null phenotypes result from premature
stop codons and the ensuing absence of myostatin protein
[22,23]. In contrast, Piedmontese cattle have the myostatin
missense mutation G938A that translates to C313Y myos-
tatin protein with the consequent loss of one of the
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tic TGF-b family cystine-knot structural motif. Compared
to wild type, Piedmontese cattle skeletal muscle C313Y
myostatin precursor protein (C313Y-MstnPP) is translated
at greatly elevated levels (> 10-fold) but the C313Y mature
growth factor (C313Y-MstnGF) is detected at significantly
reduced levels in skeletal muscle while circulating levels
are similar [10]. Refolded E. coli expressed C313Y-MstnGF
failed to inhibit muscle cell proliferation and acted as a
dominant negative inhibitor of wild type (WT) myostatin
[10].
The MstnGF monomer contains four disulphide bonds
(Figure 1, yellow), three of which are involved in an intri-
cate cystine-knot motif (C281-C340, C309-C372 and C313-
C374); C339 forms the intermolecular dimerisation disul-
phide bond. We have investigated the in vitro structure and
stability of C313Y-MstnPP and additional disulphide
mutant proteins C313A-MstnPP and C374A-MstnPP.
C313Y recapitulates the mutation found in Piedmontese
myostatin, C313A disrupts the C313-C374 disulphide bond
without introducing a large tyrosine residue minimizing
steric interference and C374A removes the same disulphide
bond through mutation of the partner cysteine residue. The
results presented here show a significant decrease in C313Y
myostatin covalent disulphide linked dimerisation, lowered
thermal stability and a failure to inhibit myoblast prolifera-
tion relative to WT. This research indicates that myostatin
structural stability and covalent dimerisation are main-
tained by the cystine-knot and suggests that this structural
motif is required for receptor-mediated signaling by the
myostatin growth factor in vivo, with its absence leading to
a double-muscled phenotype.
Results
C313 mutations decrease myostatin disulphide-linked
covalent dimerisation
All C313 mutant myostatin proteins could be refolded and
purified using the WT protocol of heparin affinity chro-
matography followed by gel filtration chromatography
[24]. Disulphide-linked dimerisation is significantly
decreased in the mutant proteins, as seen by SDS-PAGE
densitometric analysis (Figure 2A). A proportion of the
C313 myostatin mutants eluted as dimer during gel filtra-
tion chromatography (Figure 2B, peak D) but they are
not disulphide linked, owing to their monomeric Mw dis-
played on non-reducing SDS-PAGE. In addition, gel filtra-
tion chromatograms highlight increased aggregation
during refolding for all mutant proteins (Figure 2B, peaks
A1 and A2) compared to WT [24].
C313 mutant myostatin precursor protein structures are
similar to WT but show decreased stability
The circular dichroism (CD) spectra of C313Y-MstnPP,
C313A-MstnPP and C374A-MstnPP are broadly compar-
able to that of MstnPP (Figure 3A), but show decreased
absorption at 217 nm indicating that disruption of the
C313-C374 disulphide bond by mutation of C313 or
C374 compromises the integrity of b-sheet structures.
The overall similarity of the MstnPP C313 mutants’ CD
spectra to WT and other TGF-b family propeptide and
precursor protein spectra [25,26] indicates refolding was
successful. Sypro Orange fluorescence thermal shift
assays [27] show that C313Y-, C313A- and C374A-
MstnPP all have reduced thermal stability with major
unfolding transitions approximately 20°C lower than
the 86°C of MstnPP, at 66, 67 and 67°C respectively
(Figure 3B).
Structural modeling and tryptic digestion of C313Y-
myostatin precursor protein suggest structural
perturbation
In addition to disruption of the cystine-knot motif the
C313Y substitution will perturb myostatin structure.
Modeling the C313Y-MstnGF structure by directly sub-
stituting a tyrosine sidechain for cysteine at position 313
in the MstnGF crystal structure [11] using Coot [28]
showed that all energetically favoured tyrosine side chain
rotamers cannot occur without significant structural
rearrangement owing to steric interference with nearby
regions of the structure (Figure 4A). The location of 313
Figure 1 The myostatin growth factor primary structure. Disulphide bonds are shown in yellow; C313 is highlighted in blue, C374 in red
and the dimerisation C339 is boxed. Sequence numbering for the full-length precursor myostatin (MstnPP) and processed myostatin growth
factor alone (MstnGF) are shown. MstnPP numbering is used throughout this paper.
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Page 2 of 12Figure 2 Mutations in the myostatin precursor protein inhibit covalent dimerisation and increase aggregation during refolding.A .( i )
Reducing (R) versus non-reducing (NR) SDS-PAGE (12%) analysis of dimer (D) and monomer (M) ratios for purified precursor protein dimers after
gel filtration chromatography; (ii) Quantitative densitometry analysis of relative proportions of monomer and dimer for each protein. Percentages
are calculated relative to the fully reduced monomer. Statistical significance was calculated using a paired Student’s t-test where * is P < 0.0001
for monomers relative to the WT monomer and **<0.0001 for dimers relative to the WT dimer. B. Gel filtration chromatography of (i) C313Y-
MstnPP; (i) C313A-MstnPP and (iii) C374A-MstnPP. Peaks are labeled as follows: A1, void volume aggregates; A2, lower molecular weight
aggregates; D, dimer.
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Page 3 of 12Figure 3 Myostatin precursor protein disulphide mutants are structurally similar to the WT but have decreased thermal stability.A .
Circular dichroism spectra from 195 to 240 nm of MstnPP (green), C313Y-MstnPP (blue), C313A-MstnPP (black) and C374A-MstnPP (red). B.
Fluorescence-based thermal shift assay; MstnPP (green); C313Y-MstnPP (blue); C313A-MstnPP (black); C374A-MstnPP (red); and buffer only control
(orange).
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Page 4 of 12Figure 4 Structural modeling and tryptic digestion of C313Y-MstnPP suggest structural perturbation. A. Orthogonal structural
representations of the environment of residue 313 within: (i) The MstnGF crystal structure (green ribbons) highlighting the native C313-C374
disulphide bond (boxed, C313 red; C374 green stick representation) (ii) The modeled C313Y-MstnGF structure with C313 replaced by Tyr
showing a superposition of the Tyr sidechain favoured rotamers (Chi 1 angles -60°, 180°, 60°). The intermolecular disulphide (C339-C339’)i s
shown in blue stick representation. The right-hand view is rotated ~90° around the X-axis relative to the left-hand view. B. (i) Limited tryptic
proteolysis of C313Y-MstnPP. Reducing (R) and non-reducing (NR) SDS-PAGE showing bands as indicated: M, monomer; D, dimer. Tryptic
digestion was performed at 37°C with a myostatin:trypsin ratio of 100:1(w/w) and samples were taken at 0, 0.5, 1, 2, 3, 4 and 18 hour time
points. (ii) Quantification of trypsin proteolysis of C313Y-MstnPP and MstnPP [24], as a function of time, normalised to the concentration at time
zero.
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Page 5 of 12in combination with disruption of the cystine knot sug-
gests an increase in structural flexibility on removal of
disulphide bond induced structural constraints. The
resistance of C313Y-MstnPP to limited proteolysis was
investigated by incubation with trypsin at 37°C followed
by analysis using reducing (R) and non-reducing (NR)
SDS-PAGE. The C313Y-MstnPP tryptic product pattern
is very similar to WT indicative of a similar overall fold
[24]. However, the rate of C313Y-MstnPP proteolysis is
increased relative to MstnPP consistent with improved
protease accessibility owing to decreased structural com-
pactness and/or increased structural flexibility in combi-
nation with decreased dimerisation (Figure 4B). The
C313Y substitution disrupts the cystine-knot motif lead-
ing to improved protease accessibility. The MstnGF pro-
teolytic product is not observed as trypsin fails to cleave
at the RSRR furin site (unpublished results).
Furin processing and secondary structure of C313Y-
myostatin are maintained
In vivo, MstnPP is processed to give the propeptide/
growth factor dimer latent complex for export. In vitro
incubation of MstnPP and C313Y-MstnPP with furin
resulted in proteolytic processing of the proprotein to the
mature growth factor for both WT and C313Y myostatin
as evident by the monomeric growth factor product band
at 12 kDa under reducing conditions. As expected
MstnGF is a disulphide-linked dimer of 25 kDa under
non-reducing SDS-PAGE conditions but the C313Y
growth factor fails to form a disulphide-linked dimer and
exhibits increased mobility on SDS-PAGE (Figure 5A).
The failure of C313Y-MstnGF to covalently dimerise is
consistent with results observed for C313Y-MstnPP
(Figure 1A). CD analysis shows that the furin processing
of C313Y-MstnPP to C313Y latent complex (C313Y-
MstnLC) increases the proportion of b-sheet secondary
structure (Figure 5B (i)) inferring some structural rear-
rangement upon proteolytic processing. This b-sheet
increase is a reversal of the decrease seen for C313Y-
MstnPP compared to MstnPP (Figure 3A). The second-
ary structure of C313Y-MstnLC is more similar to WT
MstnLC than to C313Y-MstnPP from which it was pro-
cessed (Figure 5B (ii)). In contrast the spectra of WT
MstnPP and MstnLC are largely similar (Figure 5B (iii)).
Comparison of CD thermal melting curves for C313Y-
MstnPP and MstnPP showed no distinctive differences
in unfolding behaviour except at high temperature
(Figure 6A). The CD melting curves are representative of
a complex (i.e. not two-state, or single intermediate)
unfolding mechanism [29], as expected for myostatin
that aggregates and forms amyloid at elevated tempera-
tures [24]. CD thermal unfolding of WT and C313Y-
MstnLC suggests that the mutant latent complex has
decreased stability compared to the WT (Figure 6B)
though the differences are not as large as observed in
Sypro Orange assays that reports on hydrophobic core
solvent accessibility (Figure 3B).
C313Y myostatin growth factor proteolytically processed
from C313Y-MstnPP fails to inhibit myoblast proliferation
C313Y myostatin activity was measured by C2C12 myo-
blast proliferation assays [30-32]. Growth factor was
obtained by cleavage of MstnPP and C313Y-MstnPP with
furin convertase and acid-induced dissociation [19] of the
propeptide-growth factor latent complex. C313Y-MstnGF,
C313Y-MstnPP and C313Y-MstnLC do not inhibit myo-
blast proliferation (Figure 7). These observations are con-
sistent with studies of bovine C313Y myostatin growth
factor also expressed in E. coli but refolded directly as the
mature growth factor protein [10]. Positive control
MstnGF inhibits C2C12 myoblast proliferation compared
to cells only, buffer only, MstnPP and MstnLC controls
(Figure 7). Wild type inhibition was less dramatic than
that seen in assays performed previously [10] owing to
incomplete acid-induced dissociation of the propeptide in
the latent complex [19].
Discussion
Myostatin contains the canonical cystine-knot motif and
dimerises via an intermolecular disulphide bond as found
for nearly all TGF-b family members. Even though the
overall structures of the myostatin C313 mutants are
broadly similar to WT there is significantly less covalently
linked dimeric C313 mutant myostatin. Gel filtration chro-
matography shows that C313 mutant myostatin dimerisa-
tion can occur, but it is not mediated by an intermolecular
disulphide bond but occurs, presumably, via interactions at
the hydrophobic dimerisation interface [11]. The C313
mutation site is structurally adjacent to the inter-molecular
disulphide bond and increased structural flexibility or rear-
rangement in the absence of the C313-C374 disulphide
will lead to structural distortion in the growth factor
domain affecting disulphide-linked dimerisation. This
structural distortion may interfere with interactions
between the myostatin growth factor domain and the pro-
peptide domain and/or with its receptor. This analysis with
purified recombinant myostatin is consistent with results
showing reduced levels of dimeric myostatin in Piedmon-
tese cattle skeletal muscle compared to WT controls even
in the context of a greatly elevated mutant precursor myos-
tatin concentration [10]. The chaperone-like role of the
myostatin propeptide region for correct folding of the
growth factor motif [15,16] means that recombinant
C313Y-MstnGF prepared from furin cleavage of C313Y-
MstnPP more closely mimics in vivo production of C313Y-
MstnGF than refolding of recombinant growth factor
domain expressed in isolation. The absence of signaling
activity of C313Y-MstnGF, derived from proteolytically
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Page 6 of 12processed C313Y-MstnPP, causing no effect on C2C12
myoblast proliferation, confirms the importance of the
cystine knot motif for myostatin function. All the disul-
phide mutants, C313Y-MstnPP, C313A-MstnPP and
C374A-MstnPP, exhibit reduced thermal stability and have
an increased propensity to aggregate. These results are
consistent with the cystine-knot being required for the
high stability of myostatin as observed for other members
of this growth factor super family [33,34]. Removal of the
myostatin C313-C374 disulphide leads to an increase in
susceptibility of C313Y myostatin to proteolysis, through
decreased b-sheet structure and presumed increased flex-
ibility. Examination of the structural environment around
residue 313 reveals that perturbations in the WT myostatin
Figure 5 Furin proteolytic processing of C313Y-MstnPP and C313Y-MstnGF secondary structure is maintained. A. Analysis of (i) WT and
(ii) C313Y precursor protein furin cleavage products by reducing (R) and non-reducing (NR) 15% SDS-PAGE. WT growth factor dimer (**) and
C313Y growth factor monomer (*) under non-reducing conditions are indicated. B. Circular dichroism analysis of MstnLC and C313Y-MstnLC from
195 to 240 nm. (i) Comparison of C313Y-MstnPP (blue) and C313Y-MstnLC (black). (ii) Comparison of WT MstnPP (green) and MstnLC (red). (iii)
Comparison of C313Y-MstnLC (black) and MstnLC (red).
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Page 7 of 12Figure 6 Thermal unfolding of WT and C313Y myostatin followed by CD suggests similar behavior at high temperatures and
decreased latent complex stability. A. Myostatin precursor protein circular dichroism thermal unfolding spectra (i) MstnPP and (ii) C313Y-
MstnPP. Normalised unfolding analysis for MstnPP (blue) and C313Y-MstnPP (green) at (iii) 209 nm and (iv) 217 nm. B. Myostatin latent complex
circular dichroism thermal unfolding spectra (i) MstnLC and (ii) C313Y-MstnLC. Normalised unfolding analysis for MstnLC (red) and C313Y-MstnLC
(black) at (iii) 209 nm and (iv) 217 nm.
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tyrosine. Analysis of C313A and C374A mutations con-
firms that it is disruption of the cystine-knot by removal of
the C13-C374 disulphide bond and not by the introduction
of the tyrosine that is the dominant factor in the decreased
stability and reduced disulphide-linked dimerisation of
C313Y myostatin. Myostatin elicits cell signaling via type I
and type II Ser/Thr kinase transmembrane receptors [1].
C313 is localized near the concave surface of myostatin,
close to the type I receptor binding site [35] (Figure 8). It is
not possible to exactly predict the structural consequences
of the C313Y mutation; disruption of the cystine-knot and
decreased covalent dimerisation likely results in a less com-
pact structure that is then unsuitable for receptor activa-
tion. Alternative possible mechanisms for the loss of
C313Y myostatin function are that structural alterations
owing to the C313Y mutation result in increased binding
to myostatin negative regulators such as follistatin or dec-
orin [14,36], or altered targeting [17].
Conclusion
In summary, in vitro characterization of C313Y myostatin
shows that removal of the C313-C374 disulphide bond by
site-directed mutagenesis decreases myostatin covalent
dimerisation with subsequent loss of activity and lowered
stability. An intact cystine-knot structural motif is essen-
tial for myostatin dimerisation and function.
Methods
Production of C313Y, C313A and C374A myostatin
proteins
Mutant MstnPP expression constructs were prepared by
PCR from the WT myostatin construct described pre-
viously [24]. PCR fragments were cloned into a modified
pET vector via BamHI and XhoI restriction sites and con-
structs confirmed by sequencing. The E. coli BL21 (DE3)
expression, refolding and purification of the mutant pro-
teins was conducted using the procedure previously
described for WT myostatin [24].
Analysis of disulphide-linked dimerisation by reducing
and non-reducing SDS-PAGE
Intermolecular disulphide formation was analysed by
visualising purified myostatin (1 mg/ml) on reducing (R)
versus non-reducing (NR) SDS-PAGE. All conditions were
identical except for the presence (R) or absence (NR) of
reducing agent (b-mercaptoethanol, 1.4 M) in the SDS
sample buffer. Band densities were quantified with a
Figure 7 C313Y-MstnGF is unable to inhibit the proliferation of C2C12 myoblasts. The difference in absorbance at 450 and 630 nm
correlates to cell density after incubation with WT or C313Y myostatin growth factor, precursor protein or latent complex. Cells incubated in
media in the absence of protein but with buffer (Buffer only) or without buffer (Cells only) were used as controls. Error bars represent the
standard error of the mean for triplicate samples from three independent experiments for WT samples and two independent experiments for
C313Y. Statistical significance was calculated using a paired Student’s t-test where ** P < 0.05.
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The Student’s t-test was performed using GraphPad Prism
(GraphPad Software, Inc) using triplicate gels.
Circular dichroism spectroscopy and thermal denaturation
CD spectra in the far-UV region (195-240 nm) were mea-
sured for myostatin (1 mg/mL) with a Chirascan CD
spectrometer (Applied Biophysics) using a 0.1 mm cell at
4°C. For each sample 20 spectra of 1 nm interval were
collected every 2.5 seconds, followed by baseline subtrac-
tion, averaging and smoothing. For CD thermal denatura-
tion, 1 nm/2.5 second readings were taken at every 5°C
(precursor protein) or 10°C (latent complex) increase in
temperature from 5 - 90°C with a 30 second equilibration
time at each temperature and a tolerance level of 0.2°C.
The change in C313Y-MstnPP CD signal was normalized
by the decreased initial proportion of b-sheet for, relative
to MstnPP, before thermally-induced denaturation
(Figure 3A).
Fluorescence-based thermal shift assays
Sypro Orange (Sigma) was diluted 100x according to man-
ufacturer’s instructions in milliQ H2Ow i t h2μLt h e n
added to 18 μL myostatin (1 mg/ml in 50 mM Tris-HCl,
150 mM NaCl, pH 8.5). Negative controls contained buffer
and dye only. A Rotor-Gene 6000 thermocycler (Corbett)
was used for analysis with excitation at 470 nm and fluor-
escence emission measured at 555 nm over increasing
temperature from 30 to 95°C in 1°C increments. Melting
temperatures were calculated with the Rotor-Gene 6000
software.
Structural modeling
The myostatin coordinates from the myostatin/follistatin
complex structure (PDB code: 3HH2) were used to model
the C313Y, C313A and C374A mutations with the amino
acid substitution and rotamer tools in Coot [28]. Struc-
tural figures were prepared with PyMol [37].
Protease resistance analysis
Protease resistance was assayed by incubating C313Y-
MstnPP at a w/w ratio of 100:1 trypsin (bovine pancreas,
Sigma) at either 4°C, room temperature or 37°C. Samples
were taken after 0.5, 1, 2, 3, 4 and 18 hours (overnight),
denatured, and then analysed by reducing and non-redu-
cing SDS-PAGE. The decrease in concentration of
Figure 8 The MstnGF structure showing the proximity of the C313Y mutation site to the putative Type I receptor binding site.T h e
C313Y site is shown in one monomer only for clarity. Disulphide bonds are shown in yellow and the modeled C313Y in red. Receptor binding is
modeled by homology with interactions documented for the TGF-b growth factors [11].
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Page 10 of 12full-length C313Y-MstnPP compared to MstnPP [24] as a
function of time, normalised to the concentration at time
zero, was quantified by gel densitometry using Image-J
software [38] Owing to the different relative proportions
of MstnPP and C313Y-MstnPP monomer and dimer
under non-reducing conditions, the reduced SDS-PAGE
monomer bands were quantified enabling direct compari-
son between the two proteins.
Furin cleavage
Purified myostatin precursor protein dimer, in HEPES pH
7.5, 150 mM NaCl buffer, was concentrated to 10 mg/mL
and furin cleavage buffer (50 mM HEPES pH7.5 and
1 mM CaCl2) was added to a final volume of 250 μLp e r
1 mg of protein. Human furin convertase (Sigma, 2 U/μL)
was added at a ratio of 1 μL furin to 100 μg protein. The
reaction was incubated at 30°C for 64 hours and subse-
quently centrifuged at 17,000 × g, 4°C for 5 minutes to
remove precipitated protein.
C2C12 myoblast proliferation myostatin activity assay
C2C12 mouse myoblasts were cultured in Advanced Dul-
becco’s Modified Eagle’s Medium (4.5 g/L D-glucose and
110 mg/L sodium pyruvate; Gibco, Invitrogen) supple-
mented with 10% foetal calf serum, 4 mM L-glutamine
and penicillin/streptomycin. Cells were incubated at 37°C
in a 5% CO2 humidified environment and passaged at
80-90% confluency. Cells were plated in fresh medium in
optical bottom 96-well plates at a density of 1,000 cells/
well. After 24 hours, media was removed and 100 μL/well
fresh media containing myostatin (10 μg/mL) was added.
Equivalent concentrations of the untreated furin digest
and MstnPP were used. Activation of the MstnGF was
performed by acid treatment as described previously [19].
Cells were incubated with protein for 72 hours and cell
growth was measured using the WST-1 Cell Proliferation
Assay (Roche). WST-1 (10 μL) was added to each well and
incubated for a further 3 hours. Absorbance at 450 nm
and 630 nm was measured in a PowerWave XS 96-well
plate reader (BioTek Instruments, Inc). Cells incubated in
media only and media containing furin cleavage buffer
only were used as negative controls. Three independent
experiments each with triplicate wells were used for each
condition for WT; two independent experiments were
conducted in triplicate for C313Y. The Student’s t-test was
performed using GraphPad Prism (v5.04, GraphPad Soft-
ware, San Diego, California, USA).
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